732 related articles for article (PubMed ID: 20367536)
21. Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety.
Huggins A; Sergott RC
Curr Opin Ophthalmol; 2011 Nov; 22(6):447-50. PubMed ID: 21946305
[No Abstract] [Full Text] [Related]
22. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
Devonshire V; Havrdova E; Radue EW; O'Connor P; Zhang-Auberson L; Agoropoulou C; Häring DA; Francis G; Kappos L;
Lancet Neurol; 2012 May; 11(5):420-8. PubMed ID: 22494956
[TBL] [Abstract][Full Text] [Related]
23. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS.
Kowarik MC; Pellkofer HL; Cepok S; Korn T; Kümpfel T; Buck D; Hohlfeld R; Berthele A; Hemmer B
Neurology; 2011 Apr; 76(14):1214-21. PubMed ID: 21464424
[TBL] [Abstract][Full Text] [Related]
24. Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.
Massberg S; von Andrian UH
N Engl J Med; 2006 Sep; 355(11):1088-91. PubMed ID: 16971715
[No Abstract] [Full Text] [Related]
25. Fingolimod therapy for multiple sclerosis.
Willis MA; Cohen JA
Semin Neurol; 2013 Feb; 33(1):37-44. PubMed ID: 23709211
[TBL] [Abstract][Full Text] [Related]
26. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology.
Brinkmann V
Pharmacol Ther; 2007 Jul; 115(1):84-105. PubMed ID: 17561264
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
Lee S; Baxter DC; Limone B; Roberts MS; Coleman CI
J Med Econ; 2012; 15(6):1088-96. PubMed ID: 22583065
[TBL] [Abstract][Full Text] [Related]
28. Future clinical challenges in multiple sclerosis: Relevance to sphingosine 1-phosphate receptor modulator therapy.
Hohlfeld R; Barkhof F; Polman C
Neurology; 2011 Feb; 76(8 Suppl 3):S28-37. PubMed ID: 21339488
[TBL] [Abstract][Full Text] [Related]
29. Fingolimod.
Prescrire Int; 2011; 20(118):173-4, 176-7. PubMed ID: 21751747
[TBL] [Abstract][Full Text] [Related]
30. Fingolimod-associated macular edema: incidence, detection, and management.
Jain N; Bhatti MT
Neurology; 2012 Feb; 78(9):672-80. PubMed ID: 22371414
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
Cohen JA; Chun J
Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
[TBL] [Abstract][Full Text] [Related]
32. Fingolimod for the treatment of relapsing multiple sclerosis.
Singer BA
Expert Rev Neurother; 2013 Jun; 13(6):589-602. PubMed ID: 23738997
[TBL] [Abstract][Full Text] [Related]
33. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
Chun J; Hartung HP
Clin Neuropharmacol; 2010; 33(2):91-101. PubMed ID: 20061941
[TBL] [Abstract][Full Text] [Related]
34. Central nervous system-directed effects of FTY720 (fingolimod).
Miron VE; Schubart A; Antel JP
J Neurol Sci; 2008 Nov; 274(1-2):13-7. PubMed ID: 18678377
[TBL] [Abstract][Full Text] [Related]
35. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
Sørensen PS
J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
[TBL] [Abstract][Full Text] [Related]
36. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis.
Agashivala N; Kim E
Clin Ther; 2012 Jul; 34(7):1583-90. PubMed ID: 22749258
[TBL] [Abstract][Full Text] [Related]
38. [Basic mechanisms of action of fingolimod in relation to multiple sclerosis].
García-Merino JA; Sánchez AJ
Rev Neurol; 2012 Jul; 55(1):31-7. PubMed ID: 22718407
[TBL] [Abstract][Full Text] [Related]
39. New oral drugs for multiple sclerosis.
Gasperini C; Ruggieri S
Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371
[TBL] [Abstract][Full Text] [Related]
40. [Infections and fingolimod].
Cervera C
Rev Neurol; 2012 Aug; 55(4):227-37. PubMed ID: 22829086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]